On March 1, 2026, Rhythm Pharmaceuticals reported new data from its Phase 3 TRANSCEND trial showing a 16.4% mean BMI reduction for patients on setmelanotide compared to a 2.4% increase for the placebo group. The trial included a total of 142 patients, indicating significant effectiveness of the treatment.